Dopavision is pioneering the development of digital therapeutics in ophthalmology. We are developing a game-changing therapeutic for childhood myopia which can be easily administered by using a smartphone app. Our goal is to provide a clinically validated therapeutic to help in the fight against the global myopia crisis.
Myopia – also known as shortsightedness – is a major public health concern, expected to reach a global prevalence of 50% by 2050. It manifests as blurring of distant objects due to images focusing in front of the retina instead of falling on the retina. This is most often caused by excessive elongation of the eyeball during growth. Severe cases of myopia are associated with sight-threatening conditions, including glaucoma, cataract, retinal detachment, and myopic maculopathy.
At present, halting disease progression in children and young adults is regarded as the most promising intervention approach to prevent severe impairments at a later age. We support this myopia control strategy on our mission by providing transformative treatments and addressing the disease at an early stage, providing medical benefits for later years of life.
Our lead product is MyopiaX®, a breakthrough technology targeted at children and young adolescents. It has the potential to become the first digital therapy to control childhood myopia, leveraging our patented, light-based technology that stimulates specific photosensitive cells in the retina.
MyopiaX® is designed to achieve a medical effect while children play exciting games or use educational digital content. It runs on standard digital devices and is easy to use for children under minimal supervision of their parents. A clinical investigation is currently being prepared to evaluate the efficacy of MyopiaX®.